News | October 18, 2023
Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Prateek has more than 23 years of rich experience in Human Resource
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
Subscribe To Our Newsletter & Stay Updated
